Současné přístupy k léčbě osteoporózy

Supplementum: 1 / 2010 (Obsah)
Rubrika: Farmakoterapeutické postupy
Obor: Osteologie
Autoři: MUDr. Jan Rosa
Autoři - působiště: Diagnostické centrum Mediscan-Euromedic, Praha
Citace: 1 Schuit SCE, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004;34:195–202. 2 Kanis JA, Oden A, Johansson H, et al. FRAX® and its applications to clinical practice. Bone 2009;44:734–43. 3 FRAX–WHO Fracture Risk Assessment Tool ( 4 National Osteoporosis Foundation – Clinician’s Guide to Prevention and Treatment of Osteoporosis ( professionals/Clinicians_Guide.htm) 5 Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX – assessment and intervention thresholds for the UK. Osteoporos Int 2008; 19:1395–1408. 6 Štěpán J. Glukokortikoidy indukovaná osteoporóza: nové možnosti prevence a léčby. Interní Med 2008;10:323–6. 7 Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006; 79:129–37. 8 van Geel TA, van Helden S, Geusens PP, et al. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 2009;68:99–102. 9 Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513–21. 10 Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010–8. 11 Lems WF. Clinical relevance of vertebral fractures. Ann Rheum Dis 2007;66:2–4. 12 Schousboe JT, Vokes T, Broy SB, et al. Vertebral Fracture Assessment: the 2007 ISCD Official Positions. J Clin Densitom 2008;11:92–108. 13 Gallacher SJ, Gallagher AP, McQuillian C, The prevalence of vertebral fracture amongst patients presenting with non- -vertebral fractures. Osteoporos Int 2007;18:185–92. 14 Netelenbos JC, Lems WF, Geusens PP, et al. Spine radiographs to improve the identification of women at high risk for fractures. Osteoporos Int 2009;20:1347–52. 15 Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002; 87: 4431–7. 16 Dumitrescu B, van Helden S, ten Broeke R, et al. Evaluation of patients with a recent clinical fracture and osteoporosis, a multidisciplinary approach. BMC Musculoskelet Disord 2008;9:109. 17 Le Boff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999;281:1505–11. 18 Kuchuk NO, van Schoor NM, Pluijm SM, et al. Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res 2009,24:693–701. 19 Cauley JA, Lacroix AZ, Wu L, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008;149:242–50. 20 Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257–64. 21 Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004;291:1999–2006. 22 Dawson-Hughes B. The role of vitamin D in fracture prevention. IBMS BoneKey 2005,2:6–10. 23 Boonen S, Vanderschueren D, Haentjens P, et al. Calcium and vitamin D in the prevention and treatment of osteoporosis – a clinical update. J Intern Med 2006;259:539–52. 24 Kanis JA, Johansson H, Oden A, et al. A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int 2005;16:799–804. 25 Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008;336:262–6. 26 Heaney RP. The Vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 2005;97:13–9. 27 Woolf AD, Ākesson K. Preventing fractures in elderly people. BMJ 2003;327:89–95. 28 Sawka AM, Boulos P, Beattie K. Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 2005;16:1461–74. 29 Lock CA, Lecouturier J, Mason JM, et al. Lifestyle interventions to prevent osteoporotic fractures: a systematic review. Osteoporos Int 2006;17:20–8. 30 Riggs BL, Parfitt AM. Perspective. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005;20:177–84. 31 Warnke A, Meyer G, Bender R, et al. Predictors of adherence to the use of hip protectors in nursing home residents. J Am Geriatr Soc 2004;52:340–5. 32 Siris ES, Bilezikian JP, Rubin MR, et al. Pins and plaster aren’t enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab 2003; 88:3482–6. 33 Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9–16. 34 Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992;305:1124–8. 35 Paganini-Hill A, Ross RK, Gerkins VR, et al. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981;5:28–31. 36 Weiss NS, Ure CL, Ballard JH, et al. Decreased risks of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195–8. 37 Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321–33. 38 Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132:689–96. 39 Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21–8. 40 Cummings SR. LIFT study is discontinued. BMJ 2006;332:667. 41 Lufkin EG, Wong M, Deal C. The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. Rheum Dis Clin North Am 2001;1:163–85. 42 Martino S, Cauley JA, Barrett-Connor E, et al. Continuing Outcomes Relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751–61. 43 Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006; 295:2727–41. 44 Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923–34. 45 Ljunghall S, Gärdsell P, Johnell O, et al. Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study. Calcif Tissue Int 1991;49:17–9. 46 MacIntyre I, Stevenson JC, Whitehead MI, et al. Calcitonin for prevention of postmenopausal bone loss. Lancet 1988; 1:900–2. 47 Mazzuoli GF, Passeri M, Gennari C, et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 1986;38:3–8. 48 Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000;109:267–76. 49 Rogers, MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004;75:451–61. 50 Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcer. Arch Int Med 2001;161:107–10. 51 Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1–11. 52 Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009; 20:1353–62. 53 Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826–36. 54 Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 2009;7:12–17. 55 Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292–9. 56 Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309–18. 57 Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000;15:1006–13. 58 Reid DM, Devogelaer JP, Saag K, HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multi -centre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253–63. 59 Cummings SR, Black DM, Thompson TE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 1998;280:2077–2082. 60 Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–1541. 61 Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85:4118–24. 62 Black DM, Schwartz AV, Ensrud KE, et al. FLEX Research Group: Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927–38. 63 Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–52. 64 Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83–91. 65 McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333–40. 66 Štěpán J, Burckhardt P, Hána V. The effects of three-month intravenous ibandronate on bone density and bone remodeling in Klinefelter’s syndrome: the influence of vitamin D deficiency and hormonal status. Bone 2003;33:589–96. 67 Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9. 68 Miller PD, McClung MR, Macovei L. et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20: 1315–22. 69 Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis. One-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838–46. 70 Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22. 71 Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med 2007;357:1–11. 72 Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate- -induced osteopetrosis. N Engl J Med 2003; 349: 457–463. 73 Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999;84:3076–81. 74 Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women. A randomized controlled trial. JAMA 2003;289:2525–33. 75 Ettinger B, Bilezikian JP: For osteoporosis, are two antiresorptive drugs better than one? J Clin Endocrinol Metab 2002;87: 983–84. 76 Misof BM, Roschger P, Cosman F, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003,88:1150–6. 77 Reginster JY, Taquet AN, Fraikin G, et al. Parathyroid hormone in the treatment of involutional osteoporosis: back to the future. Osteoporos Int 1997;7(Suppl 3): S163–168. 78 Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129–34. 79 Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects of vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Min Res 2001;16:925–31. 80 Jiang YM, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) (teriparatide) improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932–41. 81 Parfitt AM. Parathyroid hormone and periosteal bone expansion. J Bone Min Res 2002;17:1741–3. 82 Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1–34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Min Res 2003;18:539–43. 83 Neer RM, Arnaut CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–41. 84 Body JJ, Gaich GA, Scheele WH, et al. A randomized double -blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528–4535. 85 Prince R, Sipos A, Hussain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20:1507–13. 86 Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028–39. 87 Greenspan SL, Bone HG, Ettinger MP. Vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. A randomized trial. Ann Intern Med 2007;146:326–39. 88 Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459–68. 89 Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporois: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005;90:2816–22. 90 Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24:153–61. 91 Cummings S, San Martin J, McClung M, et al. FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756–65.


Cílem léčby osteoporózy je prevence vzniku osteoporotických zlomenin, které jsou následkem zvýšené kostní fragility.

Celý článek je dostupný jen pro předplatitele časopisu




Více o předplatném

Jste odborný pracovník ve zdravotnictví?
Jsem odborníkem ve smyslu §2a Zákona č. 40/1995 Sb., o regulaci reklamy, ve znění pozdějších předpisů, čili jsem osobou oprávněnou předepisovat léčivé přípravky nebo osobou vydávat léčivé přípravky.

Potvrzuji, že jsem se seznámil/a s definicí odborník
dle zákona č. 40/1995 Sb.
Potvrzuji, že jsem se seznámil/a s riziky, jimž se jiná osoba než odborník vystavuje, vstoupí-li na stránky určené pro odborníky